Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990303 | 0.88 | CYP2C19 (0.39) | HRH4ADORA3ADORA2AADORA1CYP2C19 | |
| SCHEMBL12989408 | 0.79 | HRH4 (0.34) | HRH4CYP2C19 | |
| SCHEMBL22487790 | 0.77 | ADORA1 (0.38) | HRH4ADORA3ADORA2AADORA1DDAH1 | |
| SCHEMBL9178197 | 0.77 | HRH4 (0.38) | HRH4ADORA3ADORA2AADORA1DDAH1 | |
| SCHEMBL12082584 | 0.76 | HRH4 (0.41) | HRH4CYP2C19NOS1KDRFASN | |
| SCHEMBL23642016 | 0.69 | PDCD1 (0.40) | ADORA3ADORA2AADORA1DDAH1HTR2C | |
| SCHEMBL18238710 | 0.69 | ADORA3 (0.32) | ADORA3ADORA2AADORA1 | |
| SCHEMBL24835655 | 0.69 | ADORA3 (0.32) | ADORA3ADORA2AADORA1 | |
| SCHEMBL19152671 | 0.68 | SRC (0.33) | ADORA3ADORA2AADORA1DDAH1 | |
| SCHEMBL19153492 | 0.66 | ADORA3 (0.32) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404674-B2 | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311721-A1 | COMPOUNDS | CCNA1, MKI67, CCNT1 | HRH4 1985/4885ADORA3 1307/4885ADORA2A 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.